跳至主要内容
临床试验/NCT01870908
NCT01870908已完成不适用

Drug Use-result Survey to Assess the Safety and Efficacy of the Combination of Tacrolimus + Biological Agents in Daily Clinical Settings

Astellas Pharma Inc0 个研究点目标入组 664 人开始时间: 2012年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
664
主要终点
Simplified disease activity index (SDAI)

研究概览

简要总结

This study is to evaluate the safety and the effectiveness of treatment with tacrolimus and biological agents.

详细描述

The purpose of this study is to confirm the safety of 24 weeks-treatment with the combination of tacrolimus + biological agents, and to assess the efficacy using SDAI, CDAI, DAS28-CRP, MMP-3, MHAQ in patients with rheumatoid arthritis who have not achieved SDAI remission despite of using biological agents for over 8 weeks.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • patients with rheumatoid arthritis who have been treated with biological agents over 8 weeks but have not achieved SDAI remission (SDAI < 3.3)

排除标准

  • 未提供

研究组 & 干预措施

tacrolimus + biological agents

干预措施: tacrolimus (Drug)

tacrolimus + biological agents

干预措施: biological agents (Drug)

结局指标

主要结局

Simplified disease activity index (SDAI)

时间窗: Baseline and week-24

次要结局

  • Disease Activity Score 28 (DAS28)(Baseline, week-12 and week-24)
  • Clinical disease activity index (CDAI)(Baseline, week-12 and week-24)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验